Backed with $140M, startup launches three-pronged attack on liver diseases
Startup factory Third Rock Ventures is launching a three-pronged attack on liver diseases with $140 million and an unusually early and large assist from a Japanese drug maker.
Ambys Medicines Inc. will get $100 million from Takeda Pharmaceutical Co. Ltd. — including $80 million in research and development commitments — on top of $40 million from Third Rock to pursue cell therapy, gene therapy and traditional small-molecule approaches to restoring and replacing live r function lost in a variety…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Health Management | Japan Health | Liver | Liver Disease | Urology & Nephrology